Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 1/27/2019 |
| Start Date: | November 26, 2018 |
| End Date: | August 2020 |
| Contact: | Sr. Clinical Project Manager |
| Email: | aestheticclinicaltrials@galderma.com |
| Phone: | 817-961-5655 |
A Multicenter, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines
An interventional phase 2 study to evaluate safety and efficacy of AbobotulinumtoxinA
treatment for glabellar lines
treatment for glabellar lines
Inclusion Criteria:
- Moderate to severe glabellar lines at maximum frown as assessed by the Investigator
using a 4-point photographic scale (0=none, 3=severe)
- Moderate to severe glabellar lines at maximum frown as assessed by the subject using a
static 4-point categorical scale (0=none, 3=severe)
Exclusion Criteria:
- Botulinum toxin treatment in the face within 9 months prior to study treatment
We found this trial at
10
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials